ImmunoScape is a pre-clinical biotechnology brand that specializes in the discovery and development of innovative TCR-based therapeutics for solid tumors. Leveraging their Deep Immunomics and Machine Learning platforms, ImmunoScape creates a diverse portfolio of novel TCRs that target various tumor types. Their multi-pronged approach, combined with unique tumor targets, ensures the development of highly effective and differentiated T cell receptor based therapies.

With a continuous stream of unique TCR hits from their discovery engine, ImmunoScape rapidly progresses assets towards clinical candidate nomination. Their robust pipeline includes a range of cell therapy programs designed to combat solid tumors. In addition to their groundbreaking research, ImmunoScape actively contributes to the scientific community through publications and collaborations, notably in their ongoing COVID-19 collaboration with NIAID and the Johns Hopkins University.

Headquartered in Singapore and San Diego, ImmunoScape is at the forefront of advancing the field of oncology and revolutionizing cancer treatment. Follow them on their social media channels for the latest updates and breakthroughs in TCR-T cell therapies